These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 7665550)

  • 1. Topoisomerase poisons: harnessing the dark side of enzyme mechanism.
    Froelich-Ammon SJ; Osheroff N
    J Biol Chem; 1995 Sep; 270(37):21429-32. PubMed ID: 7665550
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
    Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
    Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ICE bioassay. Isolating in vivo complexes of enzyme to DNA.
    Subramanian D; Furbee CS; Muller MT
    Methods Mol Biol; 2001; 95():137-47. PubMed ID: 11089227
    [No Abstract]   [Full Text] [Related]  

  • 4. Iridoids as DNA topoisomerase I poisons.
    Gálvez M; Martín-Cordero C; Ayuso MJ
    J Enzyme Inhib Med Chem; 2005 Aug; 20(4):389-92. PubMed ID: 16206835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action.
    Perrin D; van Hille B; Barret JM; Kruczynski A; Etiévant C; Imbert T; Hill BT
    Biochem Pharmacol; 2000 Apr; 59(7):807-19. PubMed ID: 10718339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases.
    Tse-Dinh YC
    Infect Disord Drug Targets; 2007 Mar; 7(1):3-9. PubMed ID: 17346206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topoisomerase enzymes as drug targets.
    Guichard SM; Danks MK
    Curr Opin Oncol; 1999 Nov; 11(6):482-9. PubMed ID: 10550012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological activities of topopyrones.
    Zaleski PA; Maini R; Leiris SJ; Elban MA; Hecht SM
    J Nat Prod; 2012 Apr; 75(4):577-85. PubMed ID: 22462811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yeast systems for demonstrating the targets of anti-topoisomerase II agents.
    Nitiss JL; Nitiss KC
    Methods Mol Biol; 2001; 95():315-27. PubMed ID: 11089243
    [No Abstract]   [Full Text] [Related]  

  • 10. Inactivation of topoisomerase I or II may lead to recombination or to aberrant replication termination on both SV40 and yeast 2 micron DNA.
    Levac P; Moss T
    Chromosoma; 1996 Oct; 105(4):250-60. PubMed ID: 8854885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation of covalent enzyme-DNA complexes.
    Rowe TC; Grabowski D; Ganapathi R
    Methods Mol Biol; 2001; 95():129-35. PubMed ID: 11089226
    [No Abstract]   [Full Text] [Related]  

  • 12. DNA topoisomerases: essential enzymes and lethal targets.
    Chen AY; Liu LF
    Annu Rev Pharmacol Toxicol; 1994; 34():191-218. PubMed ID: 8042851
    [No Abstract]   [Full Text] [Related]  

  • 13. Lignans from the bark of Machilus thunbergii and their DNA topoisomerases I and II inhibition and cytotoxicity.
    Li G; Lee CS; Woo MH; Lee SH; Chang HW; Son JK
    Biol Pharm Bull; 2004 Jul; 27(7):1147-50. PubMed ID: 15256759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Involvement of topoisomerases in replication, transcription, and packaging of the linear adenovirus genome.
    Wong ML; Hsu MT
    J Virol; 1990 Feb; 64(2):691-9. PubMed ID: 2153235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA topoisomerases I and II inhibitory activity of constituents isolated from Juglans mandshurica.
    Li G; Lee SY; Lee KS; Lee SW; Kim SH; Lee SH; Lee CS; Woo MH; Son JK
    Arch Pharm Res; 2003 Jun; 26(6):466-70. PubMed ID: 12877556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of DNA topoisomerase inhibitors on nonhomologous and homologous recombination in mammalian cells.
    Aratani Y; Andoh T; Koyama H
    Mutat Res; 1996 Feb; 362(2):181-91. PubMed ID: 8596537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition.
    Fortune JM; Velea L; Graves DE; Utsugi T; Yamada Y; Osheroff N
    Biochemistry; 1999 Nov; 38(47):15580-6. PubMed ID: 10569942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Poisons of DNA topoisomerases I and II].
    Charcosset JY; Soues S; Laval F
    Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of topoisomerases by fatty acids.
    Suzuki K; Shono F; Kai H; Uno T; Uyeda M
    J Enzyme Inhib; 2000; 15(4):357-66. PubMed ID: 10995067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of DNA topoisomerases I and II and growth inhibition of HL-60 cells by novel acridine-based compounds.
    Janočková J; Plšíková J; Kašpárková J; Brabec V; Jendželovský R; Mikeš J; Kovaľ J; Hamuľaková S; Fedoročko P; Kuča K; Kožurková M
    Eur J Pharm Sci; 2015 Aug; 76():192-202. PubMed ID: 25960253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.